Abstract
We present the results of a nationwide survey of infectious disease consultants to identify mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor compounds and other novel targeted therapies. Nontuberculous mycobacterial infections, histoplasmosis, and invasive Staphylococcus aureus infection were all reported more frequently than was tuberculosis disease in this context.
Original language | English (US) |
---|---|
Pages (from-to) | 1738-1740 |
Number of pages | 3 |
Journal | Clinical Infectious Diseases |
Volume | 46 |
Issue number | 11 |
DOIs | |
State | Published - Jun 1 2008 |
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases